Clinical trial on the effectiveness of the Famotidine on symptoms of schizophrenic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190707044123N1

Enrollment

Registered

2019-07-15

Start date

2019-07-16

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Individuals in intervention group will receive for 6 weeks a Famotidine ( 40 mg, daily). Also patients will receive their standard Psychiatric medication(Olanzapine

Eligibility

Sex/Gender

All

Age

25 Years to 50 Years

Inclusion criteria

Inclusion criteria: The diagnosis of schizophrenia based on Diagnostic and Statistical Manual of Psychiatric Disorders (DSM5) Patients receiving second-generation drugs A year past diagnosis of schizophrenia Patients have a secondary school education

Exclusion criteria

Exclusion criteria: Sensitivity to famotidine Drug abuse Serious medical illness (Nephrology disease)

Design outcomes

Primary

Measure	Time frame
Symptoms of schizophrenia. Timepoint: The effectiveness of the treatment will be evaluated in Baseline and Six weeks after the intervention. Method of measurement: The effectiveness of the treatment will be evaluated in Baseline and Six weeks after the intervention based on the score obtained from the Wechsler Memory Scale(WMS) and Positive and Negative Symptoms of Schizophrenia(PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMona Mousaei

Rasht University of Medical Sciences

monamusaie@yahoo.com+98 13 3366 6268

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026